In 2020, the share of domestic drugs in the Russian market was assumed to be 50% – such an indicator was recorded in the state program in 2014 under the name “Development of the medical and pharmaceutical industry”, prepared by the Ministry of Industry and Trade. The implementation of this plan would make it possible, with almost one hundred percent certainty, to say that the Russian drug market is formed, is slightly dependent on imports, and the domestic drugs that are used in it are comparable to imported ones in terms of safety and efficacy, explained the representative of Biocad in 2014.
But now the Ministry of Industry and Trade would like to lower the target indicator from 50 to 32.9% in monetary terms. The ministry proposes to reduce both the plan for 2024 – from 53 to 36.4%, and plans regarding the share of domestic medical devices on the market: in 2020 from 40 to 25%, and in 2024 from 45 to 30%. The proposals are published on the regulation.gov.ru portal.